🇺🇸 FDA

Company profile · Sponsor

AstraZeneca

AstraZeneca AB

EBA8A89 · EMA pharma Södertälje, SE
Pipeline
24
Drugs
0
Patents
0

Quick answer

AstraZeneca (EBA8A89) is a pharma company. headquartered in Södertälje, SE. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EBA8A89
Exchange EMA
Company type pharma
Headquarters Södertälje, SE

Pipeline (24)

Search pipeline →

  1. A phase III, Multicentre, Open-Label, Chronic dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO)

    AstraZeneca

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 other active

    1 trial

  2. AZD0120, Bortezomib Hikma 3,5 mg Pulver zur Herstellung einer Injektionslösung, DARZALEX 1800 mg solution for injection, Dexamethason 1,5 mg JENAPHARM®, Kyprolis 10 mg powder for solution for infusion, Dexamethason 0,5 mg JENAPHARM®, Pomalidomide Zentiva 3 mg hard capsules, Pomalidomide Zentiva 2 mg hard capsules, Dexamethason 4 mg JENAPHARM, Kyprolis 30 mg powder for solution for infusion, Pomalidomide Zentiva 1 mg hard capsules, Pomalidomide Zentiva 4 mg hard capsules, Kyprolis 60 mg powder for solution f

    AstraZeneca

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  3. AZD0780 Placebo, AZD0780

    AstraZeneca

    Heterozygous familial hypercholesterolaemia

    phase 3 small molecule active

    1 trial

  4. AZD0780, AZD0780 Placebo

    AstraZeneca

    Hyperlipidemia, Atherosclerotic cardiovascular disease

    phase 3 small molecule active

    1 trial

  5. AZD0780, AZD0780 placebo

    AstraZeneca

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  6. AZD7270, AZD7270, Lokelma 5 g powder for oral suspension, AZD7270, Lokelma 5 g powder for oral suspension

    AstraZeneca

    Hyperkalaemia

    phase 3 small molecule active

    1 trial

  7. AZD8205, PACLITAXEL, DOXORUBICIN

    AstraZeneca

    B7-H4-Selected Advanced/Metastatic Endometrial Cancer.

    phase 3 small molecule active

    1 trial

  8. Anifrolumab

    AstraZeneca

    Moderate-to-severe Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  9. Anifrolumab, Anifrolumab Placebo

    AstraZeneca

    Polymyositis or dermatomyositis according to 2017 EULAR / ACR classification criteria

    phase 3 small molecule active

    1 trial

  10. Anifrolumab, Matching placebo solution for injection in aPFS; 0.8 mL fill volume

    AstraZeneca

    Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  11. BAY 1841788, NUBEQA 300 mg film-coated tablets, Saruparib, ZYTIGA 250 mg tablets, Xtandi - 40 mg film-coated tablets, ZYTIGA 500 mg film-coated tablets, Placebo to match (PTM) tablets, Abiraterone Teva 500 mg film-coated tablets

    AstraZeneca

    Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  12. Balcinrenone+Dapagliflozin, Balcinrenone+Dapagliflozin, Forxiga, Balcinrenone+Dapagliflozin, Forxiga 10 mg film-coated tablets

    AstraZeneca

    Chronic HF and comorbid impairment of kidney function who had a recent HF event to evaluate the effect of balcinrenone/dapagliflozin versus dapagliflozin alone on HF events and cardiovascular (CV) death

    phase 3 small molecule active

    1 trial

  13. Baxdrostat, Baxdrostat Placebo

    AstraZeneca

    Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.

    phase 3 small molecule active

    1 trial

  14. Baxdrostat, Baxdrostat Placebo, Baxdrostat

    AstraZeneca

    Uncontrolled hypertension (uTHN) defined as blood pressure that remains higher than goal levels despite patients being treated with 2 anti-hypertensive agents, including a diuretic. Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.

    phase 3 small molecule active

    1 trial

  15. Baxdrostat, Baxdrostat, Baxdrostat Placebo

    AstraZeneca

    Primary Aldosteronism defined by excess aldosterone secretion

    phase 3 small molecule active

    1 trial

  16. Baxdrostat, Baxdrostat, Baxdrostat, Forxiga 10 mg film-coated tablets, Baxdrostat placebo

    AstraZeneca

    Chronic kidney disease (CKD) and hypertension.

    phase 3 small molecule active

    1 trial

  17. Baxdrostat, Forxiga 10 mg film-coated tablets, Baxdrostat, Baxdrostat placebo

    AstraZeneca

    Chronic kidney disease (CKD) and hypertension.

    phase 3 small molecule active

    1 trial

  18. Benralizumab Placebo for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (APFS) for subcutaneous injection. Please refer to the IMPD documentation enclosed., Placebo, Fasenra 30 mg solution for injection in pre-filled syringe

    AstraZeneca

    Hypereosinophilic Syndrome (HES)

    phase 3 small molecule active

    1 trial

  19. CAPECITABINE, CAPECITABINE, CARBOPLATIN, Datopotamab deruxtecan, ERIBULIN MESYLATE, PACLITAXEL ALBUMIN-BOUND, PACLITAXEL

    AstraZeneca

    Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  20. CAPECITABINE, DS-8201a, INFLIXIMAB, CISPLATIN, MYCOPHENOLATE MOFETIL, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate for solution for infusion, FLUOROURACIL, Rilvegostomig, OXALIPLATIN, TRASTUZUMAB

    AstraZeneca

    HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

    phase 3 small molecule active

    1 trial

  21. CAPECITABINE, PACLITAXEL, CAPECITABINE, DS-8201a, Abraxane 5 mg/ml powder for dispersion for infusion.

    AstraZeneca

    HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.

    phase 3 small molecule active

    1 trial

  22. CARBOPLATIN, CARBOPLATIN, IPILIMUMAB, PEMETREXED, CISPLATIN, INFLIXIMAB, PEMETREXED, Mycofit, 250 mg, kapsułki twarde, NIVOLUMAB, volrustomig

    AstraZeneca

    Unresectable Pleural Mesothelioma

    phase 3 small molecule active

    1 trial

  23. CARBOPLATIN, CISPLATIN, PEMBROLIZUMAB, PEMETREXED, DS-8201a, PEMETREXED

    AstraZeneca

    Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations

    phase 3 small molecule active

    1 trial

  24. CISPLATIN, Armisarte 25 mg/ml concentrate for solution for infusion, CARBOPLATIN, PEMETREXED, TAGRISSO 80 mg film-coated tablets, PLACEBO, TAGRISSO 40 mg film-coated tablets

    AstraZeneca

    Patients with histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is AstraZeneca?

AstraZeneca (EBA8A89) is a pharma company. headquartered in Södertälje, SE. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does AstraZeneca sponsor?

We track 24 ClinicalTrials.gov-linked programs for AstraZeneca, including A phase III, Multicentre, Open-Label, Chronic dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO) and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does AstraZeneca company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.